1.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2020-05-01, Vol.26 (5), p.693-698
2.
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
by Powles, Thomas
Nature medicine, 2022-01, Vol.28 (1), p.144-153
3.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2021-03, Vol.27 (3), p.560-560
4.
High systemic and tumor-associated IL8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C Kobe C
Nature medicine, 2020-05-01, Vol.26 (5), p.693-698
